MYC and hepatocellular carcinoma: Several genetic or chemical experimental HCC models have been used to analyze potential tumor-inhibiting properties of statins in rodents: transgenic, MYC-driven HCC development was diminished by treatment with atorvastatin [25], as rosuvastatin did in mice developing HCC due to transgenic SV40-T antigen expression [26].